Drug
Orvepitant
Status:
Phase 2
Condition:
Chronic Cough
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Orvepitant is a neurokinin-1 receptor antagonist.
Study Purpose
ORV-PF-01 is a two-way, placebo-controlled, crossover study to evaluate the effect of two doses of orvepitant on cough in patients with IPF.
This drug has no clinical trials actively recruiting patients at this time.